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Abstract
Objectives. Imaging of joint inflammation provides a standard against which to derive an updated DAS for RA. Our
objectives were to develop and validate a DAS based on reweighting the DAS28 components to maximize association
with US-assessed synovitis.
Methods. Early RA patients from two observational cohorts (n= 434 and n= 117) and a clinical trial (n= 59) were
assessed at intervals up to 104 weeks from baseline; all US scans were within 1 week of clinical exam. There were
899, 163 and 183 visits in each cohort. Associations of combined US grey scale and power Doppler scores (GSPD) with
28 tender joint count and 28 swollen joint count (SJC28), CRP, ESR and general health visual analogue scale were
examined in linear mixed model regressions. Cross-validation evaluated model predictive ability. Coefficients learned
from training data defined a re-weighted DAS28 that was validated against radiographic progression in independent data
(3037 observations; 717 patients).
Results. Of the conventional DAS28 components only SJC28 and CRP were associated with GSPD in all three devel-
opment cohorts. A two-component model including SJC28 and CRP outperformed a four-component model (R2 = 0.235,
0.392, 0.380 vs 0.232, 0.380, 0.375, respectively). The re-weighted two-component DAS28CRP outperformed conven-
tional DAS28 definitions in predicting GSPD (test log-likelihood <2.6, P < 0.01), Larsen score and presence of
erosions.
Conclusion. A score based on SJC28 and CRP alone demonstrated stronger associations with synovitis and radio-
graphic progression than the original DAS28 and should be considered in research on pathophysiological manifestations
of early RA. Implications for clinical management of RA remain to be established.
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Rheumatology key messages
. Tender joint count and general health visual analogue scale are not associated with imaging-detected
inflammation.
. A two-component DAS28 shows closer association with inflammation and structural damage than the original
score.
. This new score should be considered in research on pathophysiological manifestations of early RA.
Introduction
The DAS, introduced in 1990 [1], has had a major im-
pact on the management of patients with RA. It is now
widely used in research and in many countries DAS-
based thresholds determine which patients can access
biologic therapy [2]. However, the DAS has limitations.
Despite recommendation by the European Medicines
Agency that 28-joint DAS (DAS28) remission
(DAS28< 2.6) [3] is the preferred primary outcome for
trials of agents other than NSAIDs [4], there is evidence
of continued radiographic progression in patients achiev-
ing this goal [5]. There is also recognition that two pa-
tients with the same DAS score can have different
phenotypes [6].
The DAS was developed using rheumatologists’ treat-
ment decisions to define periods of high and low disease
activity. Of the DAS components, Ritchie articular index
and 44 swollen joint count (SJC44) made the largest con-
tribution to discriminating between these states, suggest-
ing that the rheumatologists placed more importance on
joint assessments than blood markers of inflammation
(ESR) or patient subjective effects (general health visual
analogue scale; GHVAS). Updated DAS definitions have
since been introduced; to reduce assessment time, 28-
joint counts [7] may be used. Other definitions substitute
CRP for ESR [8], and omit the GHVAS [7], although these
definitions are not interchangeable [911].
All existing DAS variants were developed using the
same outcome (treatment decision) prior to the wide-
spread use of modern imaging, which has since demon-
strated disparity between clinical assessments and
imaging-detected synovitis, a possible explanation for
continued joint destruction in patients considered to be
in clinical remission [1217]. Baker et al. [18] found that
of the original DAS28 components only SJC28 and acute
phase reactant (CRP or ESR) were independently asso-
ciated with MRI-detected synovitis, despite the DAS28
being weighted most heavily for joint tenderness.
Furthermore, recent findings from the Norfolk Arthritis
Register (NOAR) and Early RA Study cohorts demon-
strated that HLA-DRB1 amino acids associated with RA
susceptibility and radiographic joint damage were asso-
ciated with SJC28 and CRP, but not 28 tender joint count
(TJC28) (GHVAS was not assessed) [19]. Thus, there are
biologically plausible reasons for differential associations
between core DAS components and RA patient
phenotypes.
In addition to SJC28 and CRP, Baker et al. found evalu-
ator’s assessment of global disease activity VAS to be
associated with MRI-detected synovitis. However,
evaluator’s assessment of global disease activity VAS is
difficult to standardize and is frequently unavailable in
large-scale (e.g. genome-wide association) studies incor-
porating existing datasets. There is therefore a need for a
short-form DAS that allows evaluation of synovitis activity
in existing large international RA cohorts.
The objectives of the current study were firstly to con-
firm whether TJC28, SJC28, CRP, ESR and GHVAS are
independently associated with imaging-detected syno-
vitis, using US combined grey scale and power Doppler
(GSPD) score as the outcome; and secondly to define a
novel re-weighted DAS28 using appropriate components,
and validate it against radiographic progression in an ex-
ternal cohort.
Methods
All patients selected for this analysis satisfied a diagnosis
of RA by 1987 ACR [20] and/or 2010 ACR/EULAR [21]
criteria.
In the development phase we selected RA patient data
from three sources: The Leeds Inflammatory Arthritis
Continuum (IACON), a single-centre observational
cohort of patients with early inflammatory arthritis re-
cruited 20102014; the Pathobiology of Early Arthritis
Cohort (PEAC), a multicentre observational cohort of pa-
tients with early RA recruited 20092015; and a clinical
trial (Infliximab as Induction Therapy in Early
Rheumatoid Arthritis; IDEA [22]), which was largely re-
cruited in Leeds and satellite centres 20062009  only
Leeds patients are included here. Validation against
radiographic progression was conducted in RA patients
selected from the Norfolk Arthritis Register (NOAR), a
primary care-based inception cohort of patients re-
cruited 19892008, presenting with recent-onset inflam-
matory polyarthritis, defined as 52 swollen joints for
>4 weeks [23].
All patients provided written informed consent for
inclusion in each of the studies, and ethical approval
was granted by the following: IACON: Leeds (West)
Research Ethics committee (09/H1307/98); IDEA:
Northern and Yorkshire Research Ethics Committee
(05/MRE03/85); PEAC: National Research Ethics
Service Committee London  Dulwich (05/Q0703/198);
and NOAR: Norwich Research Ethics committee (LREC
2003-075).
Disease activity measurements
In IACON, IDEA and PEAC, clinical assessments were
made independently of US assessments. Joint counts
included bilateral shoulders, elbows, wrists, MCPs joints
15, PIPs joints 15, knees and MTPs joints 15. Patients
completed a 100 mm global health assessment VAS. CRP
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was recorded in mg/L; for censored values (CRP< 5 mg/
L), we imputed CRP = 2 prior to analysis (see ‘Statistical
methods’ and ‘Results’ for more details). ESR was mea-
sured in mm/h. Observations were available in IACON at
0, 26, 52 and 104 weeks, in IDEA at 0, 52 and 78 weeks
and in PEAC at 0 and 26 weeks. Visits were eligible if the
US scan occurred within 1 week of the clinical
assessment.
In NOAR CRP was measured in stored serum samples
collected at 0, 5, 10 and 15 years; consequently,
DAS28CRP was only calculated at these time points.
Tender and SJCs were carried out at 0, 3, 5, 10, 15 and
20 years. A three-component (3C) DAS28 score was cal-
culated for comparison with the re-weighted DAS28, as
patient GHVAS was not available.
Ultrasound
Full details of US scanning procedures are provided in
online Supplementary material, section ‘Methods’, avail-
able at Rheumatology online. In IACON and IDEA grey
scale (GS) and power Doppler (PD) synovitis were each
scored semi-quantitatively 03 [12]; GS scores included
both synovial hyperplasia and joint effusion. Sagittal plane
views were scored. In IACON, scoring was performed by
several trained sonographers and rheumatologists. In
IDEA the majority of scoring was performed by one
expert rheumatologist. In IDEA and IACON the following
joints were scanned: wrists, MCPs 23, PIPs 23, knees,
MTPs 15. In PEAC GS and PD were scored from 04
against a standardized image atlas [24], using transverse
plane views; bilateral MCPs 15 were scanned.
Radiography
In NOAR, radiographs of the hands and feet were per-
formed during the first 10 years of follow-up and were
scored using the Larsen method [25] as previously
described [2628]. Joint erosion was defined as a cortical
break of 52 mm and was assigned a score of 52.
Radiographs were read independently, blind to sequence,
by 2 medically qualified observers (intra- and in-
ter-observer agreement for erosion presence 90% and
91%, respectively), who underwent specific training.
Disagreements on erosion status were arbitrated by a
third investigator.
Statistical methods
In IACON and IDEA, OMERACT-EULAR composite PDUS
scores that combined GS and PD at the joint level [29]
were summated across 22 joints to give GSPD.
In PEAC, GS and PD scores were simply summated
across 10 joints, to give GSPD.
In the largest dataset (IACON), within observed data,
robust regression on order statistics was used to impute
left-censored values of CRP< 5 mg/L; summary statistics
calculated for the imputed values indicated which single
value should be imputed in the main analysis. Single im-
putation was chosen over model-based imputation to pro-
vide clarity for clinicians and researchers wishing to use
the new score. The DAS28-CRP was originally derived
using high sensitivity (hs)CRP; however, it is often calcu-
lated at centres where the reporting limit is 5, leading to
variation in the values imputed for CRP< 5 mg/L.
Multiple imputation by chained equations was used to
address missing covariate data; GSPD was not included
in covariate imputation models and only patients with
observed GSPD were retained. Imputation models
included DAS28 components, transformed where appro-
priate to maintain consistency with analysis models
[ˇSCJ28, ˇTJC28, ln(ESR), ln(CRP+1), GHVAS], Health
Assessment Questionnaire Disease Index (HAQ-DI) score,
age and sex. Predictive mean matching was used to
impute all variables; results from 20 imputed datasets
were combined according to Rubin’s rules.
Conventional DAS28 scores were calculated as follows
(CRP mg/L, GHVAS mm):
4C-DAS28CRP = (0.56  ˇTJC28) + (0.28 
ˇSJC28) + (0.36  ln(CRP+1)) + (0.014  GHVAS)
+ 0.96
4C-DAS28ESR = (0.56  ˇTJC28) + (0.28 
ˇSJC28) + (0.70  ln(ESR)) + (0.014  GHVAS)
3C-DAS28CRP = [(0.56  ˇTJC28) + (0.28 
ˇSJC28) + (0.36  ln(CRP+1))]  1.10 + 1.15
In addition we calculated partial simplified disease ac-
tivity index (SDAI) clinical disease activity index (CDAI)
scores, which excluded physician VAS, as follows (CRP
mg/dL, GHVAS cm):
Partial SDAI = TJC28 + SJC28 + CRP + GHVAS
Partial CDAI = TJC28 + SJC28 + GHVAS
We modelled GSPD as a function of individual DAS28
components in linear mixed models, using 20-fold cross-
validation to evaluate predictive performance on data not
seen before; multiple imputation was not nested within
training folds. Predictor performance was evaluated as
the squared Pearson correlation (R2) between predicted
and observed US scores, concatenating all test folds into
a single dataset. The strength of evidence favouring one
model over another was evaluated as the difference in test
log-likelihoods. For each individual in the test dataset, the
log of the multivariate Gaussian likelihood of the model
given the residuals was calculated, and this test log-like-
lihood was summed over all individuals in all test folds.
The difference in test log-likelihood can be interpreted dir-
ectly as a measure of the strength of evidence favouring
one model over another. The asymptotic equivalence of
model choice by leave-one-out cross-validation and
Akaike’s information criterion (AIC) [30] implies that a dif-
ference in test log-likelihood of 2.6 natural log units is
equivalent (for comparison of linear nested models differ-
ing by two extra parameters) to P = 0.01.
To account for differences in scaling of the GSPD out-
come, ratios between coefficients obtained from each
cohort were weighted by the number of cases with non-
missing acute phase measurements to produce the final
definition for the re-weighted DAS28. For example, the
ratio of the coefficient for SJC28 to the coefficient for
CRP from each cohort was multiplied by the number of
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observations, then the values from the three cohorts were
added together and divided by the total number of obser-
vations to give the final ratio to be used in the score. We
did not attempt to scale the final score to maintain com-
patibility with the conventional DAS28 definition(s) be-
cause they were derived using entirely different methods
and existing cut-offs for remission or severity of disease
activity would not be valid for use with the new score.
As previously described [19, 28, 31], the Larsen score
was modelled as a longitudinal continuous non-normally
distributed outcome variable using a generalized linear
latent and mixed model [32] that included the covariates
age and disease duration in addition to disease activity
variables. Multivariable models including individual
DAS28 components [ˇTJC28, ˇSJC28, ln(CRP+1)]
were constructed first, followed by models that included
each DAS28 score (re-weighted 2C or conventional 3C)
individually. Effect sizes are given as a b-coefficient with
95% CIs. AIC and Bayesian information criteria were used
to determine model fit; lower values indicate better fit. The
presence of erosions of the hands and feet was treated as
a longitudinal binary variable and modelled using a
generalized estimating equation model with logit-link
function and an exchangeable within-subject correlation
structure. The quasi-AIC, the equivalent of AIC in a gen-
eralized estimating equation, was used to determine
model fit [33].
Analyses that included US were conducted in R version
3.3.1 (R Foundation for Statistical Computing, Vienna,
Austria); analyses of radiographic outcomes were carried
out in Stata v14 (StataCorp, College Station, TX, USA).
Results
Baseline characteristics of patients are provided in
Table 1. We included 889 observations in 434 IACON
patients, 163 in 59 IDEA patients, and 183 in 117 PEAC
patients who had at least one US measurement. For val-
idation against radiographic progression there were 3037
observations in 717 NOAR patients.
Imputation of CRP < 5
The median of values imputed in IACON using robust re-
gression on order statistics for values of CRP< 5 was
1.88. We therefore imputed 2 for observations of
CRP< 5. See Table 2 for numbers of cases in which this
was necessary.
Associations between DAS28 components and GSPD
Associations between DAS28 components and GSPD
were only investigated in IACON, IDEA and PEAC;
NOAR was excluded to provide external validation of the
new scale against radiographic progression.
In four-component (4C) models that included CRP, in all
three cohorts only SJC28 and CRP were independently
associated with GSPD. Results for models with two or
four individual components, using either CRP or ESR,
are presented in Table 3.
Repeating this analysis with complete case data, within
each cohort, did not alter the conclusions (data not
shown).
TABLE 1 Baseline characteristics of patients included in IACON, IDEA, PEAC and NOAR
IACON IDEA PEAC NOAR
(n=434) (n=59) (n=117) (n=717)
Age, mean (S.D.), years 56 (15) 51 (12) 51 (16) 58 (14)
Female, % (n) 70 (304/434) 72 (50/69) 68 (80/117) 69 (492/717)
Symptom duration, months 7 (4, 15) 7 (5, 10) 5 (3, 8) 8 (4, 17)
RF positive, % (n) 63 (245/392) 57 (39/68) 74 (86/116) 32 (209/644)
ACPA positive, % (n) 69 (300/432) 74 (48/65) 81 (95/117) 38 (276/717)
TJC28 4 (1, 10) 15 (8, 22) 10 (5, 15) 5 (1, 11)
SJC28 2 (0, 5) 8 (3, 11) 5 (3, 8) 5 (2, 9)
CRP, mg/L 6 (<5, 18) 21 (10, 52) 7 (<5, 18) 11 (3, 24)
ESR, mm/h 23 (10, 38) 37 (19, 65) 30 (15, 49) —
GHVAS, mm 35 (15, 57) 53 (39, 72) 72 (51, 84) —
GSa 15 (9, 22) 29 (19, 35) 15 (8, 22) —
PDa 2 (0, 6) 13 (8, 20) 2 (4, 9) —
Total Larsen scoreb — — — 5 (0, 19)
Erosions present, % (n) — — — 45 (325/717)
Values presented are median (1st quartile, 3rd quartile) unless otherwise stated. The table provides baseline demographic,
clinical and imaging characteristics of patients included in the study. aDifferent sets of joints were scanned in IACON/IDEA
compared with PEAC, and therefore the US scores are not directly comparable across all cohorts. bTotal of individual 05
scores for joints in the hands and feet. GHVAS: general health visual analogue scale; GS: grey scale; PD: power Doppler;
SJC28: 28 swollen joint count; TJC28: 28 tender joint count; IACON: The Leeds Inflammatory Arthritis Continuum; IDEA:
Infliximab as Induction Therapy in Early Rheumatoid Arthritis; PEAC: Pathobiology of Early Arthritis Cohort; NOAR: Norfolk
Arthritis Register.
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Evaluation of model fit to GSPD
In all three cohorts, both R2 and test log-likelihood values
favoured the two-component (2C) model that included
only SJC28 and the acute phase reactant over the
models containing all four components of conventional
DAS28 (Table 4). We explored adding both CRP and
ESR into the same model as SJC28; the 2C CRP model
was still consistently a better fit to GSPD in terms of R2,
although test log-likelihood for this model was slightly
higher in PEAC.
ESR was not independently associated with GSPD in
IDEA or PEAC. The 2C ESR model was a better fit than
the 4C ESR model in all three cohorts. However, the 2C
CRP model was consistently a better fit than the 2C ESR
model. Therefore, we consider the 2C CRP-based model
the most appropriate measure of global synovitis.
Derivation of re-weighted DAS28
Ratios for SJC28: CRP from the 2C models were 1.98
(IACON), 0.78 (IDEA) and 1.16 (PEAC). Weighting for the
number of non-missing CRP observations (Table 2), the
TABLE 2 Availability of DAS28 component data within
each cohort included in the development phase
IACON IDEA PEAC NOAR
Longitudinal observations, n 889 163 183 3037
Missing TJC28, n 3 0 22 0
Missing SJC28, n 3 0 2 0
Missing GHVAS 59 0 2 NA
Missing ESR, n 159 10 3 NA
Missing CRP, n 53 9 5 135
CRP values censored
(<5 mg/L), n
431 72 51 0a
The table shows the total number of observations available
in each of the included cohorts and the extent of missing
and censored data. aHigh-sensitivity CRP was collected in
NOAR. GHVAS: general health visual analogue scale;
SJC28: 28 swollen joint count; TJC28: 28 tender joint
count; IACON: The Leeds Inflammatory Arthritis
Continuum; IDEA: Infliximab as Induction Therapy in Early
Rheumatoid Arthritis; PEAC: Pathobiology of Early Arthritis
Cohort; NOAR: Norfolk Arthritis Register; NA: Not available.
TABLE 3 Coefficients for regression of global GSPD combined score onto individual DAS28 components in three
datasets
Coefficienta (95% CI)
Four-component model Two-component model
IACON IDEA PEAC IACON IDEA PEAC
With CRP
Intercept 85.44 63.28 0.48 84.32 66.74 0.78
(71.92, 98.96) (32.40, 94.15) (4.23, 3.27) (71.97, 96.66) (37.66, 95.81) (4.18, 2.63)
ln(CRP+1) 15.79 39.64 4.28 15.45 40.31 4.06
(9.95, 21.62) (23.39, 55.89) (2.65, 5.92) (9.79, 21.14) (24.78, 55.84) (2.46, 5.66)
ˇSJC28 30.48 25.70 4.54 30.61 31.40 4.69
(24.49, 36.47) (6.04, 45.36) (2.58, 6.49) (25.91, 35.31) (18.33, 44.47) (3.34, 6.03)
ˇTJC28 0.62 6.72 0.70
(4.43, 5.67) (9.57, 23.01) (1.00, 2.40)
GHVAS -0.07 -0.06 -0.04
(0.32, 0.17) (0.71, 0.60) (0.10, 0.02)
With ESR
Intercept 79.47 87.73 1.69 79.33 96.81 1.49
(69.90, 99.04) (44.15, 131.30) (2.95, 6.32) (60.12, 98.54) (54.93, 138.70) (2.97, 5.94)
ln(ESR) 11.91 10.68 1.54 11.74 12.68 1.43
(4.87, 18.94) (6.53, 27.88) (0.22, 3.31) (4.91, 18.57) (4.32, 29.67) (0.28, 3.13)
ˇSJC28 32.08 35.41 5.66 32.30 47.70 5.59
(26.06, 38.09) (14.21, 56.60) (3.59, 7.74) (27.57, 37.02) (34.39, 61.00) (4.08, 7.10)
ˇTJC28 0.49 10.11 0.15
(4.61, 5.58) (7.21, 27.43) (1.64, 1.95)
GHVAS 0.03 0.25 0.02
(0.28, 0.22) (0.43, 0.94) (0.09, 0.05)
Coefficients in this table are from linear mixed regression models containing individual DAS28 components; on the left are
results for models containing all four components; on the right are results for models containing only SJC and acute phase
(CRP or ESR). aDifferent sets of joints were scanned in IACON/IDEA compared with PEAC, and different methods were used
to calculate global GSPD combined score, and therefore the coefficients are not directly comparable across all cohorts.
GHVAS: general health visual analogue scale; GSPD: grey scale and power Doppler; SJC28: 28 swollen joint count; TJC28: 28
tender joint count; IACON: The Leeds Inflammatory Arthritis Continuum; IDEA: Infliximab as Induction Therapy in Early
Rheumatoid Arthritis; PEAC: Pathobiology of Early Arthritis Cohort; NOAR: Norfolk Arthritis Register.
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combined ratio was 1.68. This yielded the following
2C-DAS28CRP equation (imputing 2 if CRP is censored
at <5mg/L):
2CDAS28CRP ¼ˇSJC28þ

0:6 lnðCRPþ 1Þ

We then calculated DAS28 according to conventional
definitions (3C-DAS28CRP, 4C-DAS28CRP and 4C-
DAS28ESR), and according to the new 2C-DAS28CRP
defined above, in addition to partial SDAI and partial
CDAI. R2 values for the association with GSPD were
considerably higher for 2C-DAS28CRP than for the con-
ventional scores (Table 4), and large differences in test
log-likelihood confirmed that the new score outperformed
the existing definitions.
While we consider 2C-DAS28CRP the most appropriate
measure of global synovitis, to permit analysis of historical
datasets with only ESR available we constructed 2C-
DAS28ESR, using the same method to combine SJC28:
ESR coefficient ratios across the three cohorts:
2CDAS28ESR ¼ˇSJC28þ

0:32 lnðESRÞ

Associations between DAS28 components and
radiographic outcome
Results of analyses testing the association of DAS28 com-
ponents with radiographic outcomes are presented in
Table 5. TJC28 was not associated with Larsen score,
while SJC28 and CRP were both positively associated.
Higher TJC28 was associated with lower odds of erosion,
while SJC28 and CRP were both positively associated
with erosion.
Comparison between conventional and re-weighted
DAS28 scores
Conventional 3C-DAS28CRP was significantly associated
with Larsen score; however, the association was stronger
with re-weighted 2C-DAS28CRP (Table 6). Furthermore,
model fit was improved with the re-weighted 2C-
DAS28CRP score.
Conventional 3C-DAS28CRP was not associated
with the presence of erosions. However, re-weighted
2C-DAS28CRP was significantly associated with the pres-
ence of erosions. Model fit was again better with the re-
weighted 2C-DAS28CRP score.
Discussion
This is the first study to produce a 2C DAS weighted
against US-detected inflammation and demonstrate that
it outperforms the conventional definitions in the strength
of association both with synovitis and radiographic pro-
gression. The resulting 2C-DAS28CRP is a potential tool
for assessing one pathophysiological manifestation of RA,
TABLE 4 Comparison of predictions from models with varying disease activity components in test data by
cross-validation
Model
R2 between observed
and predicted values in
test data
Difference in test
log-likelihood (natural log units)
from best model
IACON IDEA PEAC IACON IDEA PEAC
Individual component models
ln(CRP) + ˇSJC28 0.236 0.392 0.380 0 0 0
ln(CRP) + ln(ESR) + ˇSJC28 0.232 0.384 0.378 4.58 4.85 0.41
ln(CRP) + ˇSJC28 + ˇTJC28 + GHVAS 0.232 0.380 0.373 1.85 3.04 1.59
ln(ESR) + ˇSJC28 0.215 0.309 0.306 19.77 7.55 9.19
ln(ESR) + ˇSJC28 + ˇTJC28 + GHVAS 0.211 0.298 0.297 22.62 12.31 10.48
DAS models
Re-weighted 2C-DAS28CRP 0.236 0.386 0.383 0 0 0
Conventional 3C-DAS28CRP 0.166 0.356 0.295 55.52 5.73 15.39
Conventional 4C-DAS28CRP 0.144 0.337 0.256 78.21 10.69 18.85
Conventional 4C-DAS28ESR 0.123 0.305 0.222 102.03 7.42 20.31
Partial SDAI 0.166 0.337 0.251 62.64 8.82 17.62
Partial CDAI 0.139 0.295 0.209 78.12 13.95 20.89
This table provides the squared Pearson correlation (R2) for a variety of different linear mixed models each predicting global
GSPD combined score, including two, three or four of the original individual DAS28 components, or a single calculated DAS;
the difference in test log-likelihood (a measure of goodness-of-fit to the outcome) is also provided for each model relative to
the best-performing model (for which difference = 0). 2C: two component; 3C: three component; 4C: four component; CDAI:
clinical disease activity index; DAS28: DAS using 28 joint counts; GHVAS: general health visual analogue scale; GSPD: grey
scale and power Doppler; SDAI: simplified disease activity index; SJC28: 28 swollen joint count; TJC28: 28 tender joint count;
IACON: The Leeds Inflammatory Arthritis Continuum; IDEA: Infliximab as Induction Therapy in Early Rheumatoid Arthritis;
PEAC: Pathobiology of Early Arthritis Cohort; NOAR: Norfolk Arthritis Register.
6 https://academic.oup.com/rheumatology
Elizabeth M. A. Hensor et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/rheum
atology/advance-article-abstract/doi/10.1093/rheum
atology/kez049/5368140 by St Bartholom
ew
's & the R
oyal London School of M
edicine and D
enistry user on 01 April 2019
i.e. synovitis, consistent with the OMERACT core set def-
inition [34].
RA DASs were intended to capture the severity of the
patient’s inflammatory symptoms. The 2C-DAS28CRP
was developed to better reflect the pathophysiological
manifestation of synovial inflammation and not a more
global construct of disease activity, as reflected in the
breadth of the OMERACT core set. Consequently, we
would not recommend replacing the conventional
DAS28 with the 2C score in clinical trials or clinical prac-
tice without due consideration of how to measure the
other core set areas. The 2C-DAS28CRP score will there-
fore be useful in studies that focus on the pathophysio-
logical manifestations of RA: these include
(pharmaco)genetic/genomic studies. It could be argued
that to identify biological factors associated with disease
activity or response to therapy, US inflammation should
be used directly as the outcome. This would have the
advantage of allowing us to separate synovitis from teno-
synovitis, although it is likely that these both fall into a
broader construct of ‘RA inflammation’ which would
remain an appropriate target for such research.
However, it is not currently possible to acquire and
score images in routine clinical settings, from which
most of the large (pharmaco)genetic/genomic datasets
have been compiled to date and are likely to be compiled
in the near future. The 2C-DAS28CRP will therefore aid
the (re)analysis of (existing) large-scale datasets and
may yield larger effect sizes for any putative associations
in comparison with existing DAS28CRP.
Our findings show that if TJC28 and patient GHVAS are
removed from the DAS28, the association with the patho-
physiological mechanism targeted by DMARDs, namely
synovial inflammation, is improved. The association was
stronger for CRP-based models than for ESR-based
models, consistent with CRP being a more sensitive and
responsive measure of inflammation than ESR, which is
an indirect measure of multiple plasma proteins and influ-
enced by age, gender, haemoglobin and serum immuno-
globulin levels, among other confounders [35].
In previous work Baker et al. [18] found that SJC28,
acute phase reactants and evaluator’s global assessment
were associated with MRI-detected synovitis, which
broadly agrees with our findings. However, we were
unable to investigate the association with physician’s
global assessment as this was not available in our co-
horts; indeed, this partly motivated the development of
the new score. For the same reason we were unable to
calculate full SDAI and CDAI scores; however, the equiva-
lent partial scores performed poorly in comparison with
2C-DAS28CRP, because they gave equal weight to
tender and swollen joints and included patient VAS,
when neither tenderness nor patient VAS were independ-
ently associated with GSPD.
In a previous attempt to update the DAS28 using US-
detected synovitis [36], TJC28 and SJC28 were replaced
with PD score from 22 joints (including MTPs and exclud-
ing elbows, shoulders and PIPs), and a count of GS syno-
vitis presence in the standard 28 joints. However,
coefficients for each term were not amended, and repla-
cing the clinical counts with US restricts the clinical utility
of the score because it requires US assessment in all
cases. Nevertheless, the authors reported stronger asso-
ciations between their US-derived DAS28 scores and
radiographic and MRI measures of structural progression
compared with the original DAS28.
There are a number of limitations to this study. A limited
amount of missing covariate data was addressed using
multiple imputation, which has been shown to reduce im-
precision and bias in the estimation of coefficients in com-
parison to ad hoc approaches such as complete case
analysis [37]. We did not collect hsCRP and therefore
opted to impute a single value for observations of
CRP< 5 to standardize practice when using the new
scale. It is possible that for patients with no swollen
joints, hsCRP would provide valuable additional informa-
tion, and a DAS using alternative weights may be more
appropriate in such circumstances. However, hsCRP is
not routinely available in the clinic, limiting application.
US assessments of different joint sets were made for
TABLE 5 Associations between individual DAS28 components and radiographic damage
Univariable models Multivariable model
Variable b-Coefficient (95% CI) P-value b-Coefficient (95% CI) P-value
Larsen score (GLLAMM)
ˇTJC 0.21 (0.47, 0.05) 0.111 0.48 (1.04, 0.08) 0.092
ˇSJC 0.67 (0.37, 0.98) 1.31  105 0.84 (0.13, 1.55) 0.020
ln(CRP+1) 1.65 (1.09, 2.22) 9.85  109 1.65 (1.07, 2.23) 2.29  108
Erosions (GEE)
ˇTJC 0.13 (0.18, -0.08) 2.30  107 0.28 (0.40, 0.16) 2.52  106
ˇSJC 0.06 (0.00, 0.11) 0.064 0.30 (0.15, 0.44) 5.21  105
ln(CRP+1) 0.30 (0.21, 0.40) 6.55  1010 0.31 (0.20, 0.42) 5.31  108
This table provides coefficients, 95% CI and P-values for univariable and multivariable longitudinal models of radiographic
progression that include individual components of conventional three-component DAS28CRP. DAS28: DAS using 28 joint
counts; GEE: generalized estimating equations; GLLAMM: generalized linear latent and mixed models; SJC: swollen joint
count; TJC: tender joint count.
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IACON/IDEA and PEAC, and the methods of calculating
GSPD differed between the cohorts. Coupled with poten-
tial case mix differences, this explains why intercepts and
coefficients differed between the cohorts, which we ad-
dressed by using ratios of the coefficients rather than the
coefficients themselves. The inclusion of cohorts repre-
senting a spectrum of disease activity and treatment is
desirable in a validation study. Despite the differences in
case mix evident in Table 1, and the differences in US
methodology, patterns of association between DAS28
components and the US outcome were the same across
the development cohorts. The validation cohort was re-
cruited prior to the introduction of rapid DMARD escal-
ation for management of RA; therefore, the level of
radiographic progression may have been higher than we
would expect in modern cohorts. However, greater range
in the outcome is desirable when studying associations
and, importantly, we identified the same patterns of asso-
ciation, this time replacing US inflammation with its pos-
ited consequence, radiographic progression, as the
outcome. We chose not to rely on observed coefficients
so our results would be widely generalizable across varied
cohorts. Furthermore, any differences between cohorts
could not have affected the finding that 2C-DAS28CRP
was more strongly associated with the outcome than ori-
ginal DAS28 within each cohort. Study design is an im-
portant consideration when US methods are not
standardized; it would not be appropriate to directly com-
pare levels of inflammation between cohorts such as the
ones included in this study. However, our results show
that with the use of carefully selected methods (such as
using ratios rather than measured coefficients) it is pos-
sible to derive clinically meaningful results by combining
data from a range of US scoring systems. In future, ad-
vances in machine learning for feature extraction and
scoring may help improve standardization. GS scoring
may reflect fibrosis in addition to inflammation; we have
only included patients with early RA in this development
study, which should limit the impact of this issue, but may
also limit the applicability of the scale for use in patients
with more established disease. Future areas of validation
work for the new scale will include reassessment of
treatment effects in historical trials of both early and es-
tablished RA, in addition to prospective data collection.
In summary, a re-weighted DAS28 equation including
only SJC28 and CRP was more closely associated with
US-detected synovitis than definitions that also included
TJC28 and GHVAS. CRP-based DASs were more closely
associated with synovitis than ESR-based counterparts.
The 2C-DAS28CRP showed stronger association with
burden of radiographic damage than the conventional
3C-DAS28 including TJC28. The improved association
with both synovitis and erosion demonstrates that the
novel 2C-DAS28 is a more appropriate measure of patho-
physiology in early RA compared with conventional
DAS28.
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